Anti-alpha-synuclein Oligomer mAb
Multiple System Atrophy (MSA)
Key Facts
About BioArctic AB
BioArctic AB is a research-intensive Swedish biopharma focused on translating novel insights into protein aggregation pathology into transformative treatments for neurodegenerative diseases. Its strategic triumph is the Eisai-partnered anti-amyloid beta protofibril antibody lecanemab (Leqembi®), which achieved FDA approval in 2023, validating the company's core scientific thesis. The company's strategy balances revenue from this landmark partnership with advancing a wholly-owned pipeline targeting alpha-synuclein in Parkinson's disease, leveraging its proprietary BrainTransporter® platform to enhance drug delivery to the brain. With a market cap nearing $28 billion, BioArctic stands as a premier European biotech success story.
View full company profileTherapeutic Areas
Other Multiple System Atrophy (MSA) Drugs
| Drug | Company | Phase |
|---|---|---|
| HB-adMSCs for Multiple System Atrophy | Hope Biosciences | Phase 1/2 |
| Anti-alpha-synuclein program for MSA (acquired by AC Immune) | AFFiRiS | Phase 1 |
| MSA Program | ProMIS Neurosciences | Preclinical |
| anle138b | Modag | Phase 1/2 |
| Novel Neuroscience Candidate | Teva Pharmaceutical Industries | Phase 2 |
| ATH434 | Alterity Therapeutics | Phase 2 |